COP-AF: Colchicine did not reduce AF or myocardial injury after non-cardiac surgery, but post-hoc analysis suggest benefit in composite outcomes
Key Points This trial randomizing patients aged 55 or older to colchicine or placebo following non-cardiac thoracic surgery found no difference in the co-primary... Read more.
NOAH-AFNET 6: No benefit of oral anticoagulation among patients with atrial high-rate episodes in the absence of confirmed AF
Key Points This trial randomized elderly patients without a known diagnosis of atrial fibrillation with device-detected atrial high-rate episodes (AHREs) and a median... Read more.
HOST-IDEA: 3-Month DAPT Noninferior to 12-Month DAPT in Patients Undergoing PCI using third-generation stents
Key Points: Among patients undergoing PCI using third-generation DES with ultrathin struts and advanced polymer technology, 3- to 6-month DAPT was noninferior to... Read more.
UK Biobank Analysis: Self-reported LCHF Diet May be Linked to Cardiac Events
Key Points: In spite of the increase popularity of low-carbohydrate high-fat diet due to purported benefit in a variety of conditions, there is limited data on the... Read more.
hsCRP is a Stronger Predictor of CV Events and Death than LDL-C in High-Risk Patients on Statins
Key Points: Both inflammatory risk and hyperlipidemia and crucial risk factors for MACE in patients at high risk of CVD. In a large collaborative study of patients... Read more.
FREEDOM COVID: Therapeutic dose anticoagulation does not reduce MACE in non-critically ill COVID-19 patients
Key Points: There have been conflicting data on the role and recommended dosage of anticoagulation in non-critically-ill patients with COVID-19. In the open-label... Read more.
STELLAR: Sotatercept improves 6MWD in PAH patients and WHO FC II-III
Key Points: Sotatercept is a novel activin signaling inhibitor which was designed to target pulmonary vascular remodeling in PAH. In the STELLAR study, sotatercept... Read more.
Dapagliflozin Reduces PCWP at Rest and Exercise, Plasma Volume, and Weight in HFpEF patients
Key Points: SGLT2i therapy reduces HF hospitalizations and CV mortality in HFpEF, but the mechanism is not yet clear. In this single-center, double-blinded RCT,... Read more.
A Novel, Oral, PSCK-9 Inhibitor Showed Significant and Dose-dependent Reduction of LDL compared to Placebo
Key Points -Lowering LDL-C is known to reduce the risk of ASCVD -In patients at very high risk for ASCVD or in those with intolerance to statins, PCSK-9 inhibitors... Read more.
LIVE HCM Trial: Vigorous Exercise in Patients with HCM Not Associated with Increased Risk of Adverse Cardiac Events
Key Points -HCM is the most common cause of sudden cardiac death in athletes -In patient diagnosed with HCM, long-established guidelines have advocated against vigorous... Read more.
